P. Kushner

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
P Kushner, Peter J Kushner, P. J. Kushner, Peter Kushner, Peter J. Kushner, P J Kushner, P. Kushner
Publication record
78 papers · 10,967 citations · H-index 37

PAPERS

Abstract P2-24-07: Combination of complete estrogen receptor antagonist, OP-1250, and CDK4/6 inhibitors enhances tumor suppression and inhibition of cell cycle-related gene expression
20233 citationsauthor #7
Abstract 5375: Precision run-on sequencing (PRO-seq) analysis of a treatment time course in ER+ breast cancer cell lines reveals the transcriptional changes underlying response to complete estrogen receptor antagonist (CERAN) OP-1250
20221 citationsauthor #7
Abstract 1618: OP-1250 prevents tumor spread in a model of metastatic mutant ERα+ breast cancer
20220 citationsauthor #8
Abstract P1-17-12: Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer
202214 citationsauthor #10
Abstract P5-08-07: The complete estrogen receptor antagonist OP-1250 can combine with HER2 inhibition to inhibit estrogen receptor-driven cellular proliferation and shrink xenograft tumors in ER+/HER2+ breast cancer models
20220 citationsauthor #10
Abstract OT-09-10: A phase I/II open-label, first-in-human, multicenter, dose escalation and dose expansion study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer
20212 citationsauthor #6
Abstract LB122: The complete estrogen receptor antagonist (CERAN) OP-1250 shrinks ER+ brain metastases in an intracranial xenograft tumor model expressing mutant ESR1
20213 citationsauthor #7
Abstract PS18-16: The complete estrogen receptor antagonist OP-1250 shrinks tumors in xenograft models and has favorable preclinical pharmacokinetic attributes
20213 citationsauthor #7
Abstract 4376: OP-1250, a complete estrogen receptor antagonist (CERAN) that shrinks estrogen receptor positive tumors and exhibits favorable pharmacokinetics
20206 citationsauthor #5
Abstract P5-05-02: Preclinical development of OP-1250, an oral complete estrogen receptor antagonist (CERAN) that shrinks ER-positive breast tumors in xenograft models
20205 citationsauthor #5
OP-1250: A potent orally available complete antagonist of estrogen receptor-mediated signaling that shrinks wild type and mutant breast tumors
20206 citationsauthor #7
Estrogen Receptor Alpha Ligand Binding Domain in Complex with OP1156
20180 citationsauthor #9
Estrogen Receptor Alpha Ligand Binding Domain in Complex with OP1074
20180 citationsauthor #9
Estrogen Receptor Alpha Ligand Binding Domain in Complex with OP1154
20181 citationsauthor #9
Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity
20180 citationsauthor #10
FUNCTIONAL ESTROGEN RECEPTORS FOR PROGNOSS OF CANCER
20170 citationsauthor #3
Enhancing Hormonal Therapy for Breast Cancer by Combination with a Well-Known Approved Pharmaceutical with Little Toxicity
20080 citationsauthor #1
Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF‐1 receptor tyrosine kinases, blocks the growth of HER2‐overexpressing human breast cancer cells
200847 citationsauthor #7
Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells
2008111 citationsauthor #4
Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells
2007102 citationsauthor #4
p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1.
200657 citationsauthor #12
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.
200557 citationsauthor #10
Cyclin D1 Antagonizes BRCA1 Repression of Estrogen Receptor α Activity
200578 citationsauthor #10
A conserved lysine in the estrogen receptor DNA binding domain regulates ligand activation profiles at AP-1 sites, possibly by controlling interactions with a modulating repressor
200425 citationsauthor #7
Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.
200355 citationsauthor #3
Differential SERM Effects on Corepressor Binding Dictate ERα Activity in Vivo *
2003128 citationsauthor #3
ERβ Binds N-CoR in the Presence of Estrogens via an LXXLL-like Motif in the N-CoR C-terminus
200349 citationsauthor #8
p300 Modulates the BRCA1 inhibition of estrogen receptor activity.
2002163 citationsauthor #10
Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist.
200240 citationsauthor #9
Design of thyroid hormone receptor antagonists from first principles.
200264 citationsauthor #13
Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression.
2002187 citationsauthor #9
Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression*
2002411 citationsauthor #9
Functional interactions between cyclin D1 and BRCA1 determine activity of ligand-bound estrogen receptor alpha
20020 citationsauthor #10
Role of direct interaction in BRCA1 inhibition of estrogen receptor activity
2001288 citationsauthor #10
A Splice Variant of Estrogen Receptor β Missing Exon 3 Displays Altered Subnuclear Localization and Capacity for Transcriptional Activation.
200174 citationsauthor #5
Direct Acetylation of the Estrogen Receptor α Hinge Region by p300 Regulates Transactivation and Hormone Sensitivity*
2001364 citationsauthor #13
Src-JNK Potentiation of Estrogen Receptor AF-1; Mechanism, and Role in Estrogen Action in Breast Cancer
20010 citationsauthor #1
A splice variant of estrogen receptor beta missing exon 3 displays altered subnuclear localization and capacity for transcriptional activation.
200134 citationsauthor #5
Growth Factors Signal to Steroid Receptors through Mitogen-activated Protein Kinase Regulation of p160 Coactivator Activity*
2001167 citationsauthor #5
An Antiestrogen-responsive Estrogen Receptor-α Mutant (D351Y) Shows Weak AF-2 Activity in the Presence of Tamoxifen*
200027 citationsauthor #6
Estrogen receptor pathways to AP-1.
2000945 citationsauthor #1
The Cellular Targets of Estrogen in Mammary Ductal Development
20000 citationsauthor #1
The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs).
2000130 citationsauthor #8
Multiple Signal Input and Output Domains of the 160-Kilodalton Nuclear Receptor Coactivator Proteins
1999275 citationsauthor #6
Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators.
1999210 citationsauthor #6
Coactivator Proteins of the 160-Kilodalton Nuclear Receptor Multiple Signal Input and Output Domains
19990 citationsauthor #6
HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DIETHYLSTILBESTROL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
19990 citationsauthor #5
The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions.
1999406 citationsauthor #11
HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
19993 citationsauthor #5
The ER/AP1 Pathway: A Window on the Cell-Specific Estrogen-like Effects of Antiestrogens
19983 citationsauthor #8
MOLECULAR AND STRUCTURAL BIOLOGY OF THYROID HORMONE RECEPTORS
1998104 citationsauthor #6
The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.
19982,600 citationsauthor #5
X-ray crystallographic and functional studies of thyroid hormone receptor.
199856 citationsauthor #5
Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors.
1998594 citationsauthor #8
Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.
1997853 citationsauthor #6
ESTROGEN AND GLUCOCORTICOIDS MODULATE TRANSCRIPTIONAL REGULATION IN A HYPOTHALAMIC CELL LINE
19970 citationsauthor #3
Estrogen receptor accessory proteins augment receptor-DNA interaction and DNA bending.
199722 citationsauthor #4
Transcriptional activities of estrogen and glucocorticoid receptors are functionally integrated at the AP-1 response element.
1997164 citationsauthor #4
Mass Spectrometry of the Human Estrogen Receptor Ligand-Binding Domain Expressed in Escherichia co/i
19950 citationsauthor #4
Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.
1995773 citationsauthor #6
Molecular characterization by mass spectrometry of the human estrogen receptor ligand-binding domain expressed in Escherichia coli.
199528 citationsauthor #4
Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens.
1995710 citationsauthor #4
Screening and characterization of estrogenic activity from a hydroxystilbene library.
199528 citationsauthor #6
Gene Activation by Antiestrogens Used in Breast Cancer Therapy via the Interaction of Estrogen Receptor and AP-1.
19950 citationsauthor #1
Eukaryotic regulatory elements lurking in plasmid DNA: the activator protein-1 site in pUC.
199453 citationsauthor #1
The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins.
1994102 citationsauthor #2
Paradoxical production of target protein using antisense RNA expression vectors.
19948 citationsauthor #4
Restoration of estrogen-dependent progesterone receptor expression in a uterine myocyte cell line.
199321 citationsauthor #2
Truncated forms of DNA-binding estrogen receptors in human breast cancer.
1991112 citationsauthor #2
Estrogen and Progesterone Receptor Analysis and Action in Breast Cancer
19893 citationsauthor #3
High Expression in Mammalian Cells Without Amplification
198953 citationsauthor #10
Expression and characterization of human apolipoprotein A-I in Chinese hamster ovary cells.
198737 citationsauthor #2
Characterization of human prorenin expressed in mammalian cells from cloned cDNA.
198647 citationsauthor #9
A plasmid that replicates in both mouse and E. coli cells.
198210 citationsauthor #1
Mutations of the hma and hm alpha loci and their bearing on the cassette model of mating type inter conversion in yeast saccharomyces cerevisiae
19800 citationsauthor #2
MUTATIONS OF THE HMa AND HMα LOCI AND THEIR BEARING ON THE CASSETTE MODEL OF MATING TYPE INTERCONVERSION IN YEAST
19798 citationsauthor #2
Control of yeast cell types by mobile genes: a test.
197937 citationsauthor #1
ESTROGEN AND PROGESTERONE RECEPTOR ANALYSIS AND ACTION IN BREAST CANCER INTRODUCTION
year unknown0 citationsauthor #3

TIMELINE

1979 45 citations

1980 0 citations

1982 10 citations

1986 47 citations

1987 37 citations

1989 56 citations

1991 112 citations

1993 21 citations

1994 163 citations

1995 1,539 citations

1997 1,039 citations

1998 3,357 citations

1999 894 citations

2000 1,102 citations

2001 927 citations

2002 865 citations

2003 232 citations

2004 25 citations

2005 135 citations

2006 57 citations

2007 102 citations

2008 158 citations

2017 0 citations

2018 1 citations

2020 17 citations

2021 8 citations

2022 15 citations

2023 3 citations

Unknown 0 citations

COAUTHOR MAP

CONCEPT FOOTPRINT